Better Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep '23 Sep 30, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Revenue	-	-	-	0.01	0.02
Revenue Growth (YoY)	-	-	-	-55.56%	-
Cost of Revenue	-	-	-	-	0.9
Gross Profit	-	-	-	0.01	-0.88
Selling, General & Admin	19.1	21.82	11.12	2.67	2.6
Research & Development	10.51	16.44	19.44	3.66	2.29
Operating Expenses	29.61	38.26	30.56	6.33	4.89
Operating Income	-29.61	-38.26	-30.56	-6.32	-5.77
Interest Expense	-1.95	-1.49	-0.19	-0.1	-0.01
Other Non Operating Income (Expenses)	-	-	-10.39	0.19	-
EBT Excluding Unusual Items	-31.56	-39.75	-41.14	-6.23	-5.78
Other Unusual Items	-	-	0.65	-	-
Pretax Income	-31.56	-39.75	-40.49	-6.23	-5.78
Income Tax Expense	0.01	0.01	-0.15	0.15	-
Net Income	-31.57	-39.76	-40.34	-6.39	-5.78
Preferred Dividends & Other Adjustments	-	-	-	1.51	2.44
Net Income to Common	-31.57	-39.76	-40.34	-7.89	-8.23
Shares Outstanding (Basic)	29	24	13	10	5
Shares Outstanding (Diluted)	29	24	13	10	5
Shares Change (YoY)	29.78%	81.46%	30.48%	109.74%	-
EPS (Basic)	-1.08	-1.69	-3.11	-0.79	-1.73
EPS (Diluted)	-1.08	-1.69	-3.11	-0.79	-1.73
Free Cash Flow	-26.13	-29.04	-30.87	-5.79	-6.27
Free Cash Flow Per Share	-0.89	-1.23	-2.38	-0.58	-1.32
Gross Margin	-	-	-	100.00%	-
Operating Margin	-	-	-	-79037.50%	-32072.22%
Profit Margin	-	-	-	-98675.00%	-45700.00%
Free Cash Flow Margin	-	-	-	-72387.50%	-34816.67%
EBITDA	-29.18	-38.21	-30.46	-6.25	-5.7
D&A For EBITDA	0.44	0.05	0.1	0.08	0.07
EBIT	-29.61	-38.26	-30.56	-6.32	-5.77
Advertising Expenses	-	0	0	0.01	-

Updated Nov 9, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.